NMD UP!
- Thread starter Anonymous
- Start date
-
- Tags
- None
So, two things: First, Burst is not more effective than Nevro. Period. Data backs up Nevro. Burst only has short-term data, which means shit to physicians who aren't on the trial. Second, I spoke with a UK pain physician who is well connected throughout Europe and rejoice STJ folks because Burst is not being removed from reimbursement.
Now for my two cents as an outsider to the SCS sales world, but still quite knowledgeable about the products, Nevro, as a poster mentioned, has handpicked its reps from the big boys and has a superior technology. Hope STJ, MDT, and BSX packed their lunch when 4Q rolls around and Nevro has filtered through hospitals' VACs.
Now for my two cents as an outsider to the SCS sales world, but still quite knowledgeable about the products, Nevro, as a poster mentioned, has handpicked its reps from the big boys and has a superior technology. Hope STJ, MDT, and BSX packed their lunch when 4Q rolls around and Nevro has filtered through hospitals' VACs.
Have to agree with both accounts from this poster. Despite shit sales leadership at the top, Nevro trumps all others in the tech category and has solid reps that were hand picked to bring immediate share over. The aftermath of that share swapping will be felt by the lazy three in Q1 '15 and celebrated by Nevro!
I have been a rep at SJM 7 years and BSX 4 years, you want to talk about shit management it comes in truck loads with these idiots. Leaders at Nevro are really good, including marketing, sales and clinical, this team gets it and the best reps have come here. I am not sure why these post are so critical and bitchy? it must be from getting beat everyday. Companies are easy to understand based on revenue and growth, SJM sucks balls big time, BSX are criminals and MDT just didn’t bother to show up.
Nevro is the cats meow folks and I am grateful to be here. For the rest of you, Fuck Off and get back into delivering pizzas.
Nevro is the cats meow folks and I am grateful to be here. For the rest of you, Fuck Off and get back into delivering pizzas.
Pull down your pants and show us your roast beef sandwich
Sucks that you and I likely have the same job. You are why people have bad impressions of sales representatives.
While Nevro is off guiding investors to a nearly 300% increase in U.S. revenue from 3Q15 to 4Q15 (off a small base I know), STJ and the others just seem to be plodding along not really sure how to combat Senza's pitch in the office.
Nevro sold 1.5 implants per US sales rep in Q3 and predicts growing exponentially to 4 implants per sales rep in Q4.
That metric actually sounds pretty depressing. 1.5 implants per US rep equates to $30K a rep per quarter. 4 implants in Q4 brings them to $85K. Arent most US territories for the big three doing somewhere around $85-100K a month??
so who of us have seen a slide in business? I for one am losing trials and implants. Could be the numbers are skewed with nevro perms coming at the end month of the qtr, post trial success. I'm seeing perms on the books here and more trials scheduled and no sign of slowing. My docs are telling me HF is working. And at the moment, I got nuttin to disprove it. Not only does data not lie, but the patients don't either.
Does anyone else have or are they planning on introducing HF into the market?????
Belgium/Netherland did it some time ago, they were probably the first believers...and now Nevro is OUT of the Country...guess why????
You are referring to STJ that is out in both of those markets due to lack of efficacy of data, you should get your facts straight first. Nevro is number one in market share and quickly owning the market in Europe. Nevro is impressive, they have data, experienced reps and the ability to own the USA in a short amount of time.
It's a reimbursement issue. St jude/spinal modulation is not approved either.
Number one in MS??????
They have data???
......that is the best post of the week in all forums!!
hahahahahahaha
The reimboursement issue is saving patients indeed!!
Nevro has dominated Europe and will do the same in the US. The only weak link in their sales structure is their VP of Sales. I think despite that, their seasoned and successful scs tenured reps will begin dominating the US market in Q1. Sorry sjm, mdt, and bsc
No argument on the VP but have to disagree with them dominating the US market. Just not going happen. Too much at stake for NMD to fall over backwards despite all their ineptitude
Hello all my little sjm friends, just finished my trunk stock loading tonight (15 trials this week) and I am owing sjm accounts, smooth as butter. I like that post! sjm is dead 